1 June 2022 in International Journal of Endorsing Health Science Research (IJEHSR)
Background: Beetroots are considered a vital source of nutrition and are usually incorporated into the daily diet to prevent different disease conditions. The therapeutic effect observed is due to the presence of active ingredients in the vegetables. The majority of our population, especially females, suffers from anemia due to malnutrition. The perseverance of this research was to explore the hematopoietic effects of lyophilized beetroot powder at different doses so they could be recommended as a nutritional supplement. Methodology: Albino rabbits weighing 1500-2000 gm of either gender were selected for the study and alienated into three sets. Set I was administered distilled water, whereas sets II and III were given lyophilized beetroot 500 mg/kg and 1000 mg/kg, correspondingly. For hematopoietic evaluation of blood, automated huma count plus was utilized. After adjusting according to their weights, lyophilized beetroot powder was suspended in distilled water and given at 500 mg/kg and 1000 mg/kg to rabbits. They were dosed once daily for two months. Results: The effects were verified before the dosing was scheduled and on the 30th day and 60th day of dosing. The outcomes presented a highly noteworthy increase (p<0.0001) in hemoglobin, erythrocyte count, hematocrit, leukocyte count, and thrombocytes by both doses. 500 mg/kg dose showed a more significant increase in leukocytes and thrombocyte count compared to 1000 mg/kg, whereas 1000 mg/kg showed a more substantial increase in erythrocytes and Hb as compared to 500 mg/kg at the conclusion of the study period. Conclusion: From the above, it can be concluded that beetroot possesses pronounced hematopoietic effects and might be beneficial as a non-pharmacological treatment for anemia and thrombocytopenia.
30 September 2026 in Journal of Basic and Clinical Health Sciences
Objective: This study aimed to evaluate the comparative assessment of Garlina and Murraya koenigii L. in hyperlipidemic rats.Material and Methods: In vivo antihyperlipidemic potential of different MURK (Murraya koenigii L.) extracts and Garlina was conducted on Wistar rats induced with high-cholesterol diet. All test samples were given at p.o. dosage of 50 mg/ kg and animals were observed for 60-days. Animal Food-intake and body weight along with lipid markers in liver and aorta were investigated. In addition to this, serum lipid biomarkers along with atherogenic index was also determined. The results compared with Atorvastatin treated group. Data is expressed as mean ± standard error mean (S.E.M) using ANOVA to determine significance. Results: MURK extracts significantly decreased body weight and food intake, in contrast to the Garlina and Atorvastatin groups. MURK-HEX (hexane) extract displayed the significant reduction of 3.83 ± 2.3 g in body weight. Similarly, MURK-hexane and MURK-EA (ethylacetate) also demonstrated the highest rate of reduction in food consumption, i.e., 65.62 ± 0.5 g and 64.61 ± 0.7 g respectively. Tissue levels of cholesterol and triacylglycerol (TAG) were measured in the liver and aorta. MURK-EA treated rats had the lowest liver cholesterol levels (130 mg/dl), while the group that received MURK-MeOH (methanol) had the lowest aortic cholesterol levels (120 mg/dl). Additionally, lower TAG levels in liver and aorta of MURK-MeOH treated group were observed, measuring 129 mg/dl and 139 mg/dl respectively. MURK-MeOH group also showed the lowest serum lipid markers, i.e., TAG, LDL, and cholesterol at 136, 144, and 48 mg/dl respectively. Further, the inverse relationship between atherogenicity index of plasma (AIP) and percent protection of treatment regime indicated that all treatment groups successfully control hyperlipidemia.Conclusion: Garlina and MURK extracts possess significant lipid lowering potential. Garlina enhanced the HDL serum levels and in turn, showed lowest AIP comparable to that of standard drug Atorvastatin.